There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

There is no substance to the rumours of a $400 billion mega-merger between AstraZeneca and Bristol Myers Squibb, according to ...

Patients in England with ultra-rare kidney disease nephropathic cystinosis will soon be able to access a therapy that has ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...

Sentiment towards Novo Nordisk was also hit by the acknowledgement that it has decided to abandon the development of ...

The only smudge in the financial picture was Lilly's recently launched oral GLP-1 agonist Foundayo (orforglipron), which brought in $98 million – below forecasts – and continues to be outsold by Novo ...

News of the expanded cost-reduction drive came as Pfizer recorded 1% sales growth to $15 billion, driven by continued strong ...

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry. A Harvard ...

Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours ...

What does FDA's proposed DTC advertising rule mean for pharm... Last month, the FDA quietly added a proposed rule to the 2026 ...

Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

A one-time $5.7 billion charge related to the just-completed $6.7 billion takeover of Terns Pharma and its oral BCR-ABL ...